Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H2 2017 Summary Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 6, 3, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Women's Health, Metabolic Disorders, Dermatology, Immunology and Male Health which include indications Breast Cancer, Multiple Sclerosis, Endometriosis, Neuropathic Pain, Prostate Cancer, Vasomotor Symptoms of Menopause (Hot Flashes), Alzheimer's Disease, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Cognitive Impairment Associated With Schizophrenia (CIAS), Colon Cancer, Depression, Ductal Carcinoma In Situ, Encephalopathy, Female Contraception, Hormone Sensitive Breast Cancer, Inflammation, Metastatic Breast Cancer, Metastatic Prostate Cancer, Neurology, Obesity, Osteoporosis, Vaginal Atrophy (Atrophic Vaginitis) and Vulvar Atrophy. The latest report Estrogen Receptor Beta - Pipeline Review, H2 2017, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects - The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview 7 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 13 Products under Development by Universities/Institutes 16 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development 23 Acadia Pharmaceuticals Inc 23 AstraZeneca Plc 23 Atossa Genetics Inc 23 Chamaeleo Pharma NV 24 Eli Lilly and Company 24 Endece LLC 25 EndoCeutics Inc 25 Karo Pharma AB 26 Kissei Pharmaceutical Co Ltd 26 MEI Pharma Inc 27 Mithra Pharmaceuticals SA 27 Oasmia Pharmaceutical AB 28 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles 29 (acolbifene hydrochloride + prasterone) - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 AC-186 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 acolbifene hydrochloride - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 AUS-131 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Drug to Agonize ER-Beta for Multiple Sclerosis and Neurodegenerative Diseases - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 erteberel - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Estetrol - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 fosfestrol - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 fulvestrant - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 fulvestrant - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 KB-3944 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 KB-9520 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Loseasonique - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 NDC-1308 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 NDC-1352 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Agonize Estrogen Beta Receptor for Oncology and Inflammatory diseases - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SR-16234 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 sulfestrol - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products 59 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products 62 Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones 63 Featured News & Press Releases 63 Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective 63 Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer 63 Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer 64 Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study 65 Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 65 Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer 66 Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 66 Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 67 May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study 67 Feb 13, 2017: ENDECE Opens San Francisco Office 68 Jan 18, 2017: Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive 68 Jan 12, 2017: Mithra's North American Advisory Board For Donesta to Meet In Miami, Florida 69 Jan 09, 2017: Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter 69 Dec 08, 2016: AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX (fulvestrant) to ARIMIDEX (anastrozole) 70 Nov 29, 2016: AstraZeneca Provides Update on Faslodex at The 2016 San Antonio Breast Cancer Symposium, 6-10 December 2016, San Antonio, USA 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Number of Products under Investigation by Universities/Institutes, H2 2017 16 Products under Investigation by Universities/Institutes, H2 2017 17 Number of Products by Stage and Mechanism of Actions, H2 2017 19 Number of Products by Stage and Route of Administration, H2 2017 21 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by Acadia Pharmaceuticals Inc, H2 2017 23 Pipeline by AstraZeneca Plc, H2 2017 23 Pipeline by Atossa Genetics Inc, H2 2017 24 Pipeline by Chamaeleo Pharma NV, H2 2017 24 Pipeline by Eli Lilly and Company, H2 2017 25 Pipeline by Endece LLC, H2 2017 25 Pipeline by EndoCeutics Inc, H2 2017 25 Pipeline by Karo Pharma AB, H2 2017 26 Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 26 Pipeline by MEI Pharma Inc, H2 2017 27 Pipeline by Mithra Pharmaceuticals SA, H2 2017 27 Pipeline by Oasmia Pharmaceutical AB, H2 2017 28 Dormant Products, H2 2017 59 Dormant Products, H2 2017 (Contd..1), H2 2017 60 Dormant Products, H2 2017 (Contd..2), H2 2017 61 Discontinued Products, H2 2017 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
